Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
|
By LabMedica International staff writers Posted on 05 Aug 2019 |

Image: The ID NOW isothermal system for the qualitative detection of infectious diseases (Photo courtesy of Abbott Diagnostics).
Abbott Diagnostics (Lake Bluff, IL, USA) exhibited its range of rapid Point-of-Care (POC) diagnostics solutions at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, California, USA. The annual event held by the American Association for Clinical Chemistry (AACC) showcased the cutting-edge science and technology shaping the future of laboratory medicine.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









